A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674, and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Cilofexor (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Gilead Sciences
- 14 Nov 2016 Results presented at The Liver Meeting 2016, as per the Gilead Sciences media release.
- 26 Jul 2016 Status changed from active, no longer recruiting to completed.
- 05 Jul 2016 Planned End Date changed from 1 Aug 2016 to 1 Jul 2016.